



Anti-Tumour Treatment

Novel anticancer therapeutics targeting telomerase

Maria Ruden^{a,b,c}, Neelu Puri^{a,*}^a Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107 1822, USA

ARTICLE INFO

Article history:

Received 25 January 2012

Received in revised form 14 June 2012

Accepted 19 June 2012

Keywords:

hTERT

hTER

Telomerase inhibitor

Telomere

Cancer therapy

Oligonucleotide

G-quadruplex

GV1001

GRN163L

GRNVAC1

ABSTRACT

Telomeres are protective caps at the ends of human chromosomes. Telomeres shorten with each successive cell division in normal human cells whereas, in tumors, they are continuously elongated by human telomerase reverse transcriptase (hTERT). Telomerase is overexpressed in 80–95% of cancers and is present in very low levels or is almost undetectable in normal cells. Because telomerase plays a pivotal role in cancer cell growth it may serve as an ideal target for anticancer therapeutics. Inhibition of telomerase may lead to a decrease of telomere length resulting in cell senescence and apoptosis in telomerase positive tumors. Several strategies of telomerase inhibition are reviewed, including small molecule inhibitors, antisense oligonucleotides, immunotherapies and gene therapies, targeting the hTERT or the ribonucleoprotein subunit hTER. G-quadruplex stabilizers, tankyrase and HSP90 inhibitors targeting telomere and telomerase assembly, and T-oligo approach are also covered. Based on this review, the most promising current telomerase targeting therapeutics are the antisense oligonucleotide inhibitor GRN163L and immunotherapies that use dendritic cells (GRVAC1), hTERT peptide (GV1001) or cryptic peptides (Vx-001). Most of these agents have entered phase I and II clinical trials in patients with various tumors, and have shown good response rates as evidenced by a reduction in tumor cell growth, increased overall disease survival, disease stabilization in advanced staged tumors and complete/partial responses. Most therapeutics have shown to be more effective when used in combination with standard therapies, resulting in concomitant telomere shortening and tumor mass shrinkage, as well as preventing tumor relapse and resistance to single agent therapy.

© 2012 Elsevier Ltd. All rights reserved.

Introduction

Telomeres are specialized structures at the ends of human chromosomes that were discovered in 1985 by Elizabeth Blackburn and Carol Greider.^{1,2} Telomeres are composed of 1000–2000 non-coding tandem repeats of TTAGGG nucleotide DNA sequences and serve as protective “caps” at the ends of chromosomes, protecting them from DNA degradation and unwanted repair.^{1–4} In normal human cells telomeres shorten with each successive cell division, and upon reaching critical lengths they elicit DNA-damage responses thus activating cell cycle check points leading to cell senescence and apoptosis. In contrast, cancer cells which develop chromosomal aberrations show activation or re-activation of telomerase upon exposure to a DNA damage signal, thereby bypassing

cell cycle checkpoints and leading to uncontrolled growth and proliferation (Fig. 1).^{4,5}

Telomerase is a human ribonucleoprotein reverse transcriptase (hTERT) composed of two main subunits: the catalytic protein hTERT and the ribonucleoprotein template hTER.^{1,4,6,7} Telomerase synthesizes telomeric DNA by continually adding single stranded TTAGGG sequences onto the single stranded 3' end of telomere in the 5' to 3' direction.^{1,4,8} Telomerase consists of 451 nucleotides but only the 11-base region, consisting of nucleotides 46 through 56 (5'-CUAACCCUAAC-3'), serves as the template for telomere synthesis (Fig. 2).^{1,9,10}

An increase in telomerase activity is often directly correlated with uncontrolled growth of cells, which is a known hallmark of cancer.^{11,12} Telomerase, and specifically its catalytic subunit hTERT, is overactive in 85–90% of most cancers^{6,13} and has become a widely acceptable tumor marker and a popular target for anticancer therapeutics. In normal non-malignant cells telomerase is present in embryonic, male germline and some adult stem cells. In most somatic cells telomerase is present in very low or almost undetectable levels and is less active or inactive compared to cancer cells.^{1,4,5,14,15} One of the advantages of telomerase targeting therapies is that rapidly proliferating cancer cells have shorter telomeres (5 kb) compared to normal somatic cells and stem cells

* Corresponding author. Address: University of Illinois College of Medicine at Rockford, Department of Biomedical Sciences, 1601 Parkview Avenue, Rockford, IL 61107, USA. Tel.: +1 815 395 5678; fax: +1 815 395 5666.

E-mail address: neelupur@uic.edu (N. Puri).

^b Both authors contributed equally.

^c Present address: Department of Medicine, University of Illinois at Chicago, 900 S Ashland Ave., Suite 3306 (M/C 767), Chicago, IL 60607 4067, USA. Tel.: +1 312 355 5953; fax: +1 312 268 6226.




Fig. 1. Telomeres shortening in normal vs. cancer cells.




Fig. 2. Targeting telomerase with small molecules and AS-ODNs. Telomeres are composed of 1000–2000 oligonucleotides of non-coding G-rich nucleotide sequences, $(TTAGGG)_n$, that form a 3'-overhang on the 3' end of chromosomes.^{8,9,111} The RNA template of telomerase (hTER) consists of a total of 451 nucleotides of which nucleotides 46 through 56 (5'-CUAACCCUAAC-3') serve as a template for adding new telomeric repeats.^{10,111} GRN163L is a 13-mer oligonucleotide that inhibits telomerase by acting as a direct telomerase RNA template antagonist binding with high specificity and affinity at the active site of hTER, leading to a complete inhibition of the enzyme.^{5,24} GRN163L is currently in 12 phase I/II clinical trials (Table 3). BIBR1532 (2-[E]-3-naphtalen-2-yl-but-2-enylamino]-benzoic acid) is non-competitive non-nucleosidic mixed type hTERT active site inhibitor.²⁵ BIBR1532 is a small molecule telomerase inhibitor, which impairs the DNA substrate elongation upon template copying by reducing the number of TTAGGG repeats.³²

(10–20 kb) that have not yet reached critical lengths due to the end replication problem that occurs as a result of aging.^{14,16} By *de novo* synthesizing TTAGGG repeats, telomerase can maintain cancer cell telomeres at stable length at all times, ensuring their rapid proliferating potential and immortal capacity. Therefore, telomerase upregulation is considered to be a critical step in cell tumorigenesis. The difference in telomere lengths and telomerase activity in normal and cancer cells explains an induced therapeutics cytotoxicity on cancer cells while having a minimal impact on normal cells.¹⁰

Under normal aging conditions, telomeres become shorter with each cell division and lose their G-rich nucleotide sequences.¹⁷ To maintain proper activity of telomeres (required for protection of chromosomal integrity) a 150–250 nucleotide-long single-stranded G-rich 3' overhang forms one of the two higher order structures, a T-loop or a G-quadruplex complex, which can help maintain proper activity of telomeres (Fig. 3).^{17–19} Shelterin complex is a set of specialized proteins that are responsible for maintaining the T-loop structure by capping the telomeres and aiding in telomere-telomerase assembly (Fig. 3).^{1,4–6} The T-loop

structure is also protected from the exposure to extracellular DNA damage or repair mechanisms by multiple copies of POT1 (protection of telomerase) protein, an important ssDNA binding protein in humans.^{18–21} Therefore, by targeting telomere-associated proteins, the T-loop structure can become compromised, resulting in a significant telomere shortening and premature cell death. A G-quadruplex is another higher order structure, formed by stacking of guanine (G) tetrads by incorporating a 16-nucleotide d(GGTTAGGGTTAGGGT) and a 6-nucleotide d(TAGGGT) sequence of telomeric 3' overhang, folded via hydrogen-bonding (Fig. 3).^{18,19} The G-quadruplex protects the telomeric 3'-overhang from being accessed by telomerase, thereby regulating its catalytic activity.^{18,19} By stabilizing the G-quadruplex with small molecule ligands such as BRACO19, RHPS4 and telomestatin, the telomeric 3' overhang can be locked in place thus blocking telomerase from accessing telomeres.

There are two general strategies of telomerase targeting in cancer treatment. One is targeting telomerase directly by inhibiting the activity of its catalytic subunit (hTERT) or its RNA template




Fig. 3. T-loop and G-quadruplex. T-loop and G-quadruplex are higher order structures of telomerase required for proper maintenance of telomeres and protection of chromosome integrity. The T-loop consists of a 150–250 nucleotides long single-stranded G-rich 3' overhang.^{17,18} A D-loop is a 3'-stranded region, which serves as the primer for telomerase elongation of telomeres.¹⁹ The 6 proteins, located on the chromosomal terminus of telomeres, form a Shelterin complex and are required for capping of telomeric ends and regulation of telomere length.^{1,4–6} The POT1 protein binds to the single-stranded region of telomere and forms a heterodimer with the TPP1 protein, which links it with the dsDNA of telomere and the rest of the Shelterin complex proteins.¹⁹ TRF1/2 bind the double-stranded region of telomere. TRF1/2 are important regulators of telomere length, whereas TRF1 serves as a negative regulator of telomeres by blocking telomerase access to telomeres, TRF2 serves a protective function by preventing telomere uncapping.⁴ The model of G-quadruplex depicted here is one of a few possible versions of G-quadruplexes.¹⁹

Table 1
Strategies of targeting telomeres and telomerase.

| Therapeutic approach | Target | Mechanism | Inhibitors |
|---|------------------------------|--|--|
| Small molecule inhibitors | hTERT | Direct enzyme inhibition via active site binding | BIBR1532 |
| Antisense oligonucleotides (AS-ODN)s | hTER | Targeting RNA template of telomerase | GRN163L |
| Immunotherapy | hTERT | Using hTERT peptides to elicit CD4+ and CD8+ immune responses | GV1001, GRNVAC1/2, Vx-001 |
| Gene therapy | hTERT | hTERT promoter driven tumor cell lysis; hTERT promoter activated enzyme prodrug therapy inducing tumor cell lysis | Telomelysin Ad-hTERT-NTR/ CB1954 hTERTp-HRP/IAA |
| G-quadruplex Stabilizers | G-quadruplex | Blocking telomerase access to telomeres; uncapping of telomeres; mimicking of ssDNA overhang exposure | BRACO19 RHPS4 Telomestatin |
| Telomere and telomerase associated proteins | HSP90 | Disruption of telomerase assembly resulting in a nonfunctional telomerase | Geldanamycin (GA) Curcumin |
| T-oligo approach | Tankyrase G-rich overhang | Preventing dissociation of TRF1 leading to blocking of telomerase inducing DNA damage responses by mimicking telomeric DNA overhang exposure | PARP inhibitors N/A |

(hTER), leading to inhibition of telomerase activity (TA), telomere shortening and inhibition of cell proliferation. Another strategy is targeting the telomerase subunit indirectly with G-quadruplex stabilizers, Tankyrase or HSP90 inhibitors, thus blocking telomerase access to telomeres or inhibiting binding of telomerase-associated proteins leading to telomere uncapping and cell apoptosis.^{3,11}

One of the most recent approaches of telomere targeting is the T-oligo approach, which can induce DNA damage responses leading to tumor cell apoptosis or inhibition of cell proliferation.^{4,5,14,22} The most novel therapeutics reviewed here are small molecule inhibitors, antisense oligonucleotides, immunotherapies, gene therapies, G-quadruplex stabilizers, telomere and telomerase associated protein inhibitors, and T-oligo (Table 1).

Antisense oligonucleotides (AS-ODNs) – targeting hTER

Advantages of antisense oligonucleotide inhibitors

The antisense oligonucleotides (AS-ODNs) approach for targeting telomerase was first derived using AS-ODNs to block the trans-

lation of mRNA with a sequence complementary to sense RNA. It was initially used as an anticancer treatment in 1995.^{16,23} AS-ODNs can be used to target the catalytic component of telomerase (hTERT) or the RNA template (hTER) and are composed of short single-stranded DNA (ss-DNA) sequences that inhibit TA by complementary binding to the RNA template.¹⁶ AS-ODNs have been studied intensively and their structure has been modified and significantly improved over the past decade. One of the advantages of this approach is that AS-ODNs do not promote multidrug resistance mechanisms (MDR).^{3,24} Currently the most successful AS-ODNs in development is GRN163L (Imetelstat[®]) (Geron Corporation, Menlo Park, CA).

GRN163L – an AS-ODN telomerase inhibitor

GRN163, was the first most promising oligonucleotide and the first-generation lead compound targeting hTER, is a N3'-P5'-thio-phosphoramidate, which require a lipid carrier molecule and a lipid-based transfection agent to effectively traverse cell and tissue membranes.^{5,24} While GRN163 showed good results in inhibiting

Table 2
GRN163L in preclinical studies.

| Tumor type | Effect of treatment |
|--------------------------|--|
| Multiple Myeloma (MM) | Effective inhibition of TA in MM and CSCs; induction of cell death due to apoptosis and significant reduction in tumor cells growth; inhibition of clonogenicity and expression of CSC markers; enhanced myeloma cell death in combination treatment with HSP90 inhibitor 17AGG. ^{112,113} |
| Lung cancer | Dose- and sequence-dependent inhibition of TA; rapid alteration of cell morphology and reduction in cellular attachment and surface spreading; reduction of colony formation and prevention of cell metastases <i>in vitro</i> and <i>in vivo</i> . ^{114,115} |
| Breast cancer | Inhibition of TA; induction of DNA damage response; sensitization to radiation and chemo-therapies; synergistic effect with cisplatin, trastuzumab (HER2 ⁺ breast cancer cell line), paclitaxel; inhibition of cell migration; reduction of tumor growth, clonogenicity, cell invasion and metastases; restoration of sensitivity in drug-resistant cells. ^{31,116–120} |
| Bladder cancer | Significant inhibition of TA; morphological alterations in tumor cells; growth arrest in G0/G1 phase. ⁷ |
| Glioblastoma (GBM) | Dose-dependent inhibition of TA; reduction in cell proliferation and apoptosis in GBM TICs; ability to cross BBB; preferential accumulation in intracerebral tumors; successful inhibition of tumor growth in intracerebral human tumor xenograft model; enhanced cell survival and activation of DNA damage response pathways in combination with IR and temozolomide treatment. ^{121,122} |
| Prostate cancer | Inhibition of TA in prostate TICs; reduction of TICs, TIC markers and their capacity of self-renewal. ¹²³ |
| Hepatoma (liver cancer) | Dose-dependent inhibition of TA and tumor cell growth <i>in vitro</i> and <i>in vivo</i> ; reduction of cell proliferation and tumor growth; increased apoptosis and sensitivity due to doxorubicin treatment. ¹²⁴ |
| Pancreatic cancer | Inhibition of TA in bulk tumors and TIC subpopulations; reduction in tumor engraftment concomitant with reduction in TIC numbers; inhibition of cell growth and apoptosis with prolonged treatment; reduced tumorigenicity <i>in vivo</i> . ¹²⁵ |
| Barrett's adenocarcinoma | Inhibition of TA; induction of senescence or apoptosis; enhanced inhibition of cell proliferation with combination of doxorubicin and ritonavir; significant reduction in tumor size. ¹²⁶ |

TA, telomerase activity; CSCs, cancer stem cells; TICs, tumor-initiating cells; BBB, blood brain barrier.

telomerase, however, the lack of a lipid carrier has diminished its potential due to limited uptake. To solve this problem, a lipid-modified version, the GRN163L, has been developed.²⁴ GRN163L is a 13-mer oligonucleotide N3'-P5'-thio-phosphoramidate with a covalently bound lipophilic palmitoyl (C16) group attached to its 5'-thio-phosphate.⁷ GRN163L causes inhibition of TA by acting as a direct telomerase RNA template antagonist. GRN163L does not act like a normal antisense oligonucleotide, but with its 5'-Palmitoyl-TAGGGTTAGACAA-3' oligonucleotide chain, complementary to the hTER region of telomerase, it partially overlaps the hTER template by binding with high specificity and affinity at its active site, leading to complete inhibition of the enzyme (Fig. 2).^{7,24}

Studies have found that GRN163L may be slightly less potent than the GRN163 in a cell-free telomere repeat amplification protocol (TRAP) assay, possibly due to some interference of the lipid moiety with the telomerase template.²⁵ However, in a study with 13 solid and hematologic tumor cell lines, GRN163L has shown an IC₅₀ range between 0.8 and 6.5 mg/mL, with the average T_{1/2} being 2.9–5.3 h for 5–15 mg/kg intravenously administered drug.²⁶ This indicates that GRN163L has better cell and tissue penetration, as evidenced by its low IC₅₀ values, and greater biodistribution in normal and cancer cell lines, possibly due to the fact that it does not require a lipid carrier and can traverse membranes more effectively than GRN163.^{24,25} In addition, *in vivo* studies with a human hepatoma tumor xenograft mouse model have shown that, when administered parenterally, GRN163L has a greater uptake than GRN163.²⁴

GRN163L - Preclinical Studies (Table 2)

See Supplement for additional information.

GRN163L – clinical trials

After showing hopeful results in multiple preclinical studies, GRN163L has been moved into six stage I and stage I/II clinical trials targeting patients with chronic lymphoproliferative diseases (CLD), refractory and relapsed solid tumor malignancies, refractory and relapsed MM, locally recurrent or metastatic breast cancer (MBC), and advanced and metastatic non-small cell lung cancer (NSCLC). More information on these trials can be found in Table 3. To determine the maximum tolerated dose (MTD), including dose limiting toxicities (DLT), doses of GRN163L were escalated contin-

ually in each cohort study based on 3 or 4-week cycles until MTD was reached.²⁴

In a phase I study of GRN163L in combination with paclitaxel and bevacizumab in patients with locally recurrent or metastatic breast cancer, a total of 14 patients were treated, 3 with *de novo* MBC and 6 with prior (neo) adjuvant taxane therapy. Due to a dose escalation design, the majority of patients (78.6%) experienced dose reductions/delays with GRN163L and/or paclitaxel during later treatment cycles. The objective response rate (ORR) (measurable response) was 38.5% and, currently, alternative dosing schedules are being tested.²⁷ In a phase I clinical trial in patients with relapsed or refractory MM and phase I trial in patients with advanced solid tumors, MTD's were determined, with most prominent DLTs being thrombocytopenia and active prolonged thromboplastin time (aPTT) in the first trial, and thrombocytopenia and hypersensitivity reactions in the second trial, which have appeared in later treatment cycles only.^{28,29} The results of preliminary clinical trials show good tolerability to GRN163L despite some minor toxicities and adverse events, such as neutropenia and thrombocytopenia, myelosuppression and hypersensitivity reactions, as well as prolonged time to coagulation (prolonged aPTT), which are commonly seen in the oligonucleotide class of drugs.^{24,29}

Based on good preliminary results of GRN163L in phase I clinical trials, patients with NSCLC, locally recurrent or metastatic breast cancer, previously treated MM and patients with essential thrombocythemia (ET) are currently being recruited for phase II clinical trials with GRN163L. The objective of the phase II trials in patients with ET is to evaluate the efficacy of GRN163L as measured by hematological response (decrease in platelet count) in those patients who require cytoreduction or have failed to respond or tolerate previous therapies or have refused standard of care.³⁰ In addition, since preclinical studies with GRN163L showed that it can restore sensitivity of HER2+ breast cancer cell lines to trastuzumab,³¹ patients with HER2+ breast cancers are currently being recruited into a phase I clinical trial (see Table 3 for more info).

Small molecule inhibitors – targeting hTERT

BIBR1532

Currently, there have been only a few successful hTERT inhibitors developed. BIBR1532 (2-[E]-3-naphthalen-2-yl-but-2-enyl)ami-

Table 3
GRN163L in clinical trials.

| Phase/ identifier | Status/start–end* | Condition | Drug interventions | Outcome measures | Current results/Ref. |
|---------------------|--------------------------|---------------------------------------|---|---|--|
| I NCT00124189 | Ongoing 7/05–3/10 | CLD | GRN163L | Safety, tolerability, DLT, MTD, PK, PD | Trial ongoing, no study results yet available |
| I NCT00310895 | Ongoing 3/06–9/10 | Solid tumor malignancies | GRN163L | Safety, DLT, MTD, PK, disease response | 31 treated; 4 remain on study; MTD in range 9.4–11.7 mg/kg/d1,d8 of 21d cy; DLT – thrombocytopenia, myelosuppression and hypersensitivity reactions. ¹²⁹ |
| I NCT00594126 | Ongoing 11/07–3/10 | Multiple myeloma | GRN163L | Safety, MTD, PK, PD, efficacy | DLT – thrombocytopenia & aPTT; MTD in range of 4.8–7.2 mg/kg/2hr IV/t.i.w. ²⁸ |
| I NCT00510445 | Ongoing 6/07–8/10 | Non-small cell lung cancer | GRN163L, paclitaxel (P), carboplatin (C) | Safety, MTD, PK, efficacy | Trial ongoing, no study results yet available |
| I NCT00718601 | Ongoing 7/08–12/10 | Multiple myeloma | GRN163L, bortezomib, dexamethasone | MTD, Safety, PK, efficacy | Trial ongoing, no study results yet available |
| I/II NCT00732056 | Ongoing 7/08/12/10 | Recurrent or metastatic breast cancer | GRN163L, paclitaxel (P), bevacizumab (B) | Safety, MTD, efficacy, PK, efficacy | 14 treated; 2 remain on study; dose delays of GRN163L and/ or P in later cycles; ORR 38.5%. ²⁷ |
| II NCT01137968 | Recruiting 5/10–2/12 | Non-small cell lung cancer | GRN163L, bevacizumab | PFS, ORR, time to all-cause mortality, safety, tolerability | Trial ongoing, no study results yet available |
| II NCT01256762 | Recruiting 11/10–2/13 | Recurrent or metastatic breast cancer | GRN163L, paclitaxel with or without bevacizumab | PFS, ORR, clinical benefit rate, safety, tolerability | Trial ongoing, no study results yet available |
| II NCT01243073 | Recruiting 12/10–1/13 | Essential thrombocythemia | GRN163L, standard of care | Hematologic response, safety, tolerability, number of patients with hematological toxicities, non-heme grade 3 and 4 AEs and hemorrhagic events | Trial ongoing, no study results yet available |
| II NCT01242930 | Recruiting 12/10–2/13 | Multiple myeloma | GRN163L, standard of care | PFS, ORR, safety, tolerability, number of patients with hematological toxicities | Trial ongoing, no study results yet available |
| I NCT01265927 | Recruiting 1/11–1/14 | HER2+Breast cancer | GRN163L, trastuzumab | DLT, PK, ORR, PFS, safety and biologic effects of GRN163L in combination with trastuzumab | Trial ongoing, no study results yet available |
| I NCT01273090 | Recruiting 5/11–11/14 | Solid tumors or lymphoma | GRN163L | MTD, toxicities, PK, biologic effects, effect on telomeres and telomerase | Trial ongoing, no study results yet available |

DLT, dose limiting toxicity; MTD, maximum tolerated dose; PK, pharmacokinetics; PD, pharmacodynamics; PFS, progression free survival; ORR, objective response rate; AEs, adverse events; aPTT, active thromboplastin time; t.i.w., three times a week.

* Study end dates are estimated.

Table 4
Vaccines in clinical trials.

| Vaccine formulation | Condition | Phase, (n) Status | Immune response | Outcomes/Ref. |
|--------------------------------------|--------------------------------|----------------------------|---|---|
| GV1001, temozolomide (T), GM-CSF | Melanoma (stage IV) | I/II, (n = 25) completed | 17/21 (81%) | <i>Safety:</i> no major toxicity. <i>Clinical:</i> 6/25 – SD; 10/25 – PD; 1/25 – PR. ⁶⁰ |
| GV1001, I540 peptide | Melanoma (IIB-IV) | (n = 16) completed | No results yet available | No data available. ⁴⁴ |
| GV1001, I540 peptide, GM-CSF | NSCLC (stage IIB, IIIB, IV) | I/II, (n = 26) completed | GV1001: 13/24 (54%); I540:2/24 (8%) | <i>Safety:</i> no major toxicity. <i>Clinical:</i> 1 – CR; 3 – SD; 1 – PD; med. OS 8.5 m, 8pts. – 12 m., 6pts. – 18 m. ¹²⁷ |
| GV1001, cyclophosphamide (C), GM-CSF | HCC | II, (n = 40) completed | No immune responses detected | <i>Safety:</i> no major toxicity. <i>Clinical:</i> 17/24 – SD; med. TTP – 1.9 m.; med. TTSP – 11.7 m; med. PFS – 1.9 m; med. OS – 11.7 m. ⁵⁷ |
| GV1001, imiquimod (I) | Pancreatic | I, (n = 14) completed | 6/13 (46%) | <i>Safety:</i> well tolerated; no major toxicity or serious AEs reported ⁵⁵ |
| GV1001, gemcitabine (G), GM-CSF | Pancreatic | II, (n = 12) completed | 7/12 (56%) | <i>Safety:</i> no major toxicity. <i>Clinical:</i> induction of IFN γ , IL-6, IL-13. ⁵⁶ |
| GV1001, imiquimod, GM-CSF, 3Gyx10, C | Pancreatic | II, (n = 39) completed | (1n = 15) – 39% (2n = 10) – 50% (3n = 14) – 64% | <i>Safety:</i> 221 AEs reported, mostly – mild to moderate; GV1001 was well tolerated in all treatment regimens. ⁵³ |
| GV1001, GM-CSF | Pancreatic | I/II, (n = 48) completed | 24/38 (63%) | <i>Safety:</i> no major toxicity/AEs. <i>Clinical:</i> med. survival for 560 μ g of GV1001–8.6 m. ⁵⁴ |
| GV1001, GM-CSF, gemcitabine (G) | Pancreatic | III, (365/520) terminated | N/A | <i>Safety:</i> grade 3–4 AEs. <i>Survival:</i> OS 7.3–5.9 m.; PFS 3.7–1.9 m.; as of 8/2008 238 deaths were recorded. ⁵⁸ |
| GV1001, GM-CSF, G, capecitabine | Pancreatic | III, (n = 1100) recruiting | N/A (recruiting) | No results available. ⁵⁹ |
| GV1001, LTX-315 | Carcinoma | I, (n = 20) recruiting | N/A (recruiting) | No results available. ⁵² |
| GRNVAC1 | Prostate | I, (n = 20) completed | 19/20 (95%) | <i>Safety:</i> no major toxicity. <i>Clinical:</i> increase in PSA Δ t and molecular clearance of circulating micrometastases. ⁶⁹ |
| GRNVAC1 | AML | II, (n = 21/33) completed | 55% | <i>Safety:</i> no major toxicity. <i>Clinical:</i> 4/19 – relapsed, 7/19 – continued vaccination. Estimated DFS: 79% in 19CR* pts, 75% – Intermediate risk, 81% – high risk. ^{71,73} |
| Vx-001 | Advanced cancers (various) | I/II, (n = 116) completed | Positive immune response (>3 yr) | <i>Safety:</i> no major toxicity. <i>Clinical:</i> 1pts. with BC – CR, 2pts. – PR, 34pts. – SD. Prolonged survival & positive correlation between immune and clinical responses ⁶¹ |
| Vx-001 | NSCLC | I/II, (n = 22) | 16/21 (76%) – early; 10/11 (91%) – late | <i>Safety:</i> no major toxicity. <i>Clinical:</i> 8/32pts. (36%) – SD; med. OS – 30.6 m. ^{64,128} |
| Vx-001 | Advanced cancers | I, (n = 19) | 13/14 (93%) – early | <i>Safety:</i> no major toxicity; no DLT at 2–6 mg doses. <i>Clinical:</i> 4/19 (21%) – SD; no CR or PR; med. OS–15.2 m. ⁶² |
| Vx-001 | NSCLC (7pts – IIIB, 6pts – IV) | I/II, (n = 13) | 7/7 (100%) | <i>Safety:</i> grade I/II toxicity. <i>Clinical:</i> 3/10pts. (30%) – SD; med. TTP – 8.1 m. (IIIB), 2.3 m. (IV). ⁶⁷ |
| Vx-001 | Advanced solid tumors | I/II (n = 71) | 29/56 (52%) –early IR; 25/30 (83%) – late IR | <i>Safety:</i> grade I toxicity. <i>Clinical:</i> 3pts. (4.2%) objective response; 22/71 (31%) – SD; med. OS – 23.5 m. (early). ⁶⁷ |
| Vx-001 | Various cancers | I/II, (n = 97) | 31% – before, 58% – early IR, 79% – late IR | <i>Immune response:</i> 24/78 (31%), 46/79 (58%), 37/47 (79%). Inverse correlation between IL-10 Tc and IFN γ . ⁶⁵ |

SD, stable disease; CR, complete response; CR*, clinical remission; PR, partial response; OS, overall survival; TTSP, time to symptomatic progression TTP, time to progression; AEs, adverse events; PFS, progression free survival; PSA Δ t, Prostate Specific Antigen doubling time; DFS, disease free survival; PD, disease progression; DTL, dose limiting toxicities.




Fig. 4. Telomerase peptide-based and DC immunotherapies. The immunotherapy approach has proven to be a convenient and a successful method for anticancer therapeutics targeting telomerase. Studies have shown that hTERT, which is normally a self-antigen molecule, is capable of producing immunogenic response by stimulating hTERT peptide-specific CTLs via MHC presentation leading to tumor cell lysis^{3,4,11,42} GV1001 is MHC class II-restricted hTERT peptide-based vaccine that has strong affinity for multiple alleles of HLA class-II alleles.^{44,45} It is injected i.d. as an MHC class-II peptide following the injection of an adjuvant. It is endogenously processed by APCs to a shorter 9–10 mer MHC class-I peptide, which is further presented by APCs as a CD8+ epitope, thus stimulating CD4+ and CD8+ responses^{44,46,47}. CD4+ T cells may generate an antitumor response that is independent of a CD8+ response, leading to recruitment and activation of macrophages and eosinophils and producing tumor-destroying free radicals.^{47,48} GRNVAC1 is a promising DC vaccine, which stimulates the CD4+ T cells and leads to secretion of cytokines IL-2, IL-5, IFN- γ , as well as some IL-4, indicating a mixed type Th1/Th2 inhibition.⁶⁹ The CD4+ T-cell response may also lead to CTL-mediated killing of hTERT expressing tumor cells. The CD8+ T cells isolated from the LAMP-hTERT group of subjects also showed the ability to secrete IL-2. These results suggest that LAMP-enhanced CD8+ and CD4+ responses may lead to the development of central memory T cells.⁶⁹

no-benzoic acid) is one of the most promising hTERT specific active site inhibitors to date.²⁵ BIBR1532 is a non-nucleotidic small molecule synthetic compound that inhibits telomerase by non-competitively binding to the active site of hTERT.^{4,32,33} BIBR1532 does not block the basic template copying steps, but specifically impairs DNA substrate elongation upon template copying by reducing the number of TTAGGG repeats (Fig. 2). Therefore, it is suspected that BIBR1532 may have an influence on the translocation of the enzyme-DNA-substrate complex or may lead to dissociation of the enzyme from the DNA substrate during template copying.³² Results from multiple studies on BIBR1532 have shown a dose-dependent inhibition of telomerase with higher concentrations of BIBR1532, and have not shown any significant effects on normal human cells.^{34,35}

Preclinical studies conducted in several human cancer cell lines have shown that treatment with BIBR1532 can repress TA and lead to tumor cell growth arrest without causing acute cytotoxicity.^{35,36} In DU145 (prostate cancer), MDA-MB-231 (breast cancer), HT1080 (fibrosarcoma cancer) and HTI-H430 (lung cancer) cell lines, treatment with BIBR1532 has shown significant telomere shortening, despite a long lag time.³⁶ In a study of BIBR1532 in chondrosarcoma cancer cell lines and germ cell tumors (GCTs), prolonged treatment with BIBR1532 led to significant telomere shortening and 80% decrease of TA in chondrosarcoma cell lines. However in GCTs, which normally have greater TA and longer telomere lengths, treatment with BIBR1532 did not completely inhibit tumor cell proliferation. Similarly, in chondrosarcoma cell lines, where the

growth of cells was inhibited in early passages, the growth of treated cells in the later passages was the same as that of untreated controls.^{35,37} In a study of BIBR1532 in p53-negative BCR-ABL positive chronic myelogenous leukemia (CML) cell lines, which have critically short telomeres of approximately 3–5 kb, BIBR1532 treatment caused significant telomere shortening without affect on their cell growth kinetics, cell morphology, rate of apoptosis or cell senescence.³⁸ This study showed that functional p53 may be required to induce the response to telomerase inhibitors in cells with critically shortened telomeres, resulting in cell death and/or apoptosis.³⁸ Additionally, critically shortened telomeres may activate p53 and serve as tumor suppressors. Since the loss of functional p53 is associated with disease progression in 30% of CML patients, p53 may serve as an important genetic marker, which could help determine effective treatment options. In another study of BIBR1532 treatment of T-PLL (T-cell prolymphocytic leukemia) cell lines, which also have short telomeres and high telomerase activity, changes in cell morphology, indicative of apoptotic cell death were observed.³⁹ Additionally, BIBR1532 can sensitize certain drug-resistant cell lines to other chemotherapies, as shown in a study with drug-resistant human promyelocytic leukemia (HL60-MX2) and breast cancer (MCF-7/Mln^R-melphalan and MCF-7/Adr^R-doxorubicin) cell lines and their drug-sensitive parental (WT) counterparts (HL60-WT and MCF7/WT), where BIBR1532 effectively inhibited TA and caused progressive telomere shortening in all cell lines except the MCF-7/Adr^R doxorubicin resistant cell line.⁴⁰

Telomerase based immunotherapies

Telomerase – a universal tumor antigen

The use of an immunotherapy approach, which was designed to induce CD8+ cytotoxic T lymphocytes (CTL) response for hTERT antigens in malignant tumors, has shown better telomerase inhibition than other therapies.⁴¹ Since telomerase is present in most cancers, its peptides are universal telomerase-associated antigens (TAAs). They are capable of producing strong immune response (IR) by eliciting both CD4+ and CD8+, T-cell responses and stimulating the hTERT peptide-specific CTL activity, potentially leading to tumor cell lysis.^{11,42,43} Telomerase is normally considered a self-antigen and should have conferred tolerance early in cell development, however, many studies show that immune tolerance to hTERT-specific antigens is not complete. Studies also show that hTERT-specific CTL's are less detectable in the peripheral blood of healthy patients compared to cancer patients.⁴³ In addition, several strategies are employed in the development of vaccines that may induce hTERT's immunogenicity and eliminate the issue of self-tolerance, such as use of adjuvants like GM-CSF or TLR-7, used in GV1001 vaccine, or use of cryptic peptide vaccines like Vx-001, in which one amino-acid residue of peptide may be replaced for another thus enhancing the affinity of that peptide to HLA molecules and stimulating production of CTLs.

Preclinical studies with hTERT peptides have led to successful progress in the development of telomerase-targeting immunotherapies and several vaccines that are currently in phase III clinical trials (Table 4). The two commonly used approaches of anticancer immunotherapies are the dendritic cell (DC) approach and the hTERT peptide vaccine approach. The most promising vaccines, GV-1001, GRNVAC1 and Vx-001 are further reviewed.³

GV1001 – hTERT peptide-based vaccine

GV1001 (KAEL-GemVax Co. Ltd., Gangnam-gu Seoul, Republic of Korea) is a 16 amino acid MHC class II-restricted hTERT peptide vaccine, which consists of amino acids 611–626 (EAR-PALLTSRLRFIPK) of the hTERT active site^{44–46} GV1001 is used in conjunction with an adjuvant, such as granulocyte-monocyte colony-stimulating factor (GM-CSF) or Toll-like receptor-7 (TLR7) agonist (imiquimod).^{46,47} This may prevent the rapid degradation and elimination of anticancer vaccine peptides before recognition by the appropriate antigen presenting cells (APCs), which may occur due to a self-tolerance to self-peptides.^{46,48} GV1001 is administered as an MHC class-II peptide, which is endogenously processed to yield a MHC class-I peptide producing both CD4+ and CD8+ responses, thus leading to a robust CTL signaling cascade and a maximum IR (Fig. 4) (93; 94). The activity of CD4+ T cells at the tumor site leads to a secretion of IFN- γ and IL-2, further stimulating CD8+ CTLs and natural killer cells (NKs), which may help to increase the infiltration and the retention of CD8+ T-cells into the tumor sites leading to upregulation and re-expression of MHC class-I molecules.^{45,47} This may have a therapeutic advantage for treatment of advanced cancers that are associated with a progressive loss of MHC class-I molecules.^{3,47,49}

A preclinical study with GV1001 in patients with hTERT positive B-cell chronic lymphocytic leukemia (B-CLL), of which 75% have overexpressed hTERT, has shown that these cells contain naturally occurring telomerase-specific T cells, which can mediate the IR to hTERT peptide 611–626 (GV1001) leading to lysis of autologous leukemic cells (92). The hTERT-positive B-CLL patients treated with GV1001 peptide-loaded DCs showed positive CD4+ and CD8+ T-cell responses without a negative effect on normal cells or autoimmunity.⁵⁰ This study has revealed that GV1001 may be an effective

method for treatment of patients with B-CLL and may be moved for testing in clinical trials.

GV1001 – clinical trials

GV1001 has successfully completed several phase I and II clinical trials conducted in patients with advanced stage melanoma, NSCLC, hepatocellular carcinoma (HCC) and in patients with pancreatic cancer^{44,51–60} (See Table 4 for details). A new large randomized phase III clinical trial (TeloVac) is currently in a recruiting phase for patients with locally advanced or metastatic pancreatic adenocarcinoma in multiple centers around the UK, with a primary aim to compare standard therapy to GV1001 and to measure the length of survival for a primary outcome measure.⁵⁹ Results and information on additional clinical trials with GV1001 may be viewed in Table 4.

See Supplement for additional information.

Vx-001 – cryptic peptide-based vaccine

Studies have shown that tumor non-specific self-antigens could prevent a self-tolerance problem often caused by self-antigens.⁶¹ The HLA-I molecules consist of dominant and cryptic peptides.⁶² The dominant peptides have a strong affinity for HLA-I alleles, are abundant on the cell surface, and are strongly immunogenic, whereas cryptic peptides are not as abundant on the cell surface, have weak HLA-I affinity and are weakly immunogenic or completely lack immunogenicity. However, unlike dominant peptides, cryptic peptides do not undergo massive clonal deletion due to their poor expression and do not induce immune tolerance. Therefore, they may be better suited to be used as a peptide antitumor vaccine therapy. In addition, using tumor non-specific antigens may be a better choice for anticancer vaccines since they are not dependant on adjuvants or the efficacy of delivery.^{61,62}

The new peptide-based anticancer therapy vaccine, Vx-001 (Vaxon Biotech, Paris, France), consists of a low affinity cryptic peptide hTERT₅₇₂ (RLFFYRKS_V) and its optimized version, the hTERT_{572Y(1)} (YLFFYRKS_V), which has the first amino-acid residue replaced with a modified tyrosine (Y1) residue.⁶³ This sequence enhances the peptide's affinity for HLA-I molecules and may circumvent the self-tolerance problem.^{61,63} Additionally, Vx-001 leads to enhanced immunogenicity of the cryptic peptide when presented by HLA-A*0201 molecules (present in 40–45% of population) without changing antigen's specificity.⁶²

Vx-001 has shown good antitumor efficacy evidenced by inhibition of tumor growth *in vivo* in HHD transgenic mice and in phase I and II clinical trials in patients with various types of tumors (Table 4).^{61,62} Vx-001 has completed a large phase I/II clinical trial in 116 patients with different types of advanced stage cancers, including patients with NSCLC, breast cancer, melanoma and cholangiocarcinoma. Vx-001 has shown strong immune response rates in cancer cells, produced long-lasting disease stabilization, and prolonged overall survival.^{62,64–67} The vaccine was well tolerated, did not induce autoimmunity and resulted only in minor toxicities, and showed a positive correlation between immune response and clinical response in patients with NSCLC.⁶¹ Vx-001 is now scheduled for testing in a phase III clinical trial in NSCLC patients.⁶¹

GRNVAC1/GRNVAC2 – dendritic cell (DC) based immunotherapy

Dendritic cells (DC) are the most efficient APCs that are capable of producing strong immune response and can be used for tumors for which potent T-cell epitopes have not yet been identified.⁶⁸ Because they are nonbiased with respect to MHC allele restriction, they can encode epitopes for multiple types of HLA alleles, which may eliminate the need for alleles testing.^{47,69} GRNVAC1 (Geron

Corporation, Menlo Park, CA) is an autologous dendritic cell vaccine capable of stimulating both CD4+ and CD8+ immune responses.⁷⁰ GRNVAC1 consists of immature DCs transfected *ex vivo* with a complete mRNA sequence, encoding hTERT and a portion of the lysosomal-associated membrane protein (LAMP-1) (Fig. 4).^{69,71,72} LAMP-1 directs the hTERT to a lysosome making it easily degradable into peptides and leading to a stronger immune response.⁶⁹

GRNVAC1 was tested in a randomized phase I clinical trial in 20 patients with metastatic prostate cancer and in a more recent phase II clinical trial in 21 patients with acute myelogenous (myeloid) leukemia (AML) (Table 4). A phase I clinical trial in patients with a metastatic prostate cancer compared the effect of hTERT mRNA-transfected DC vaccine to that of LAMP-hTERT mRNA-transfected DC vaccine (GNVAC1).⁶⁹ After three or six weekly injections, vaccinated patients have shown good tolerance with only mild side effects and no signs of autoimmunity. In this trial the LAMP-hTERT group of patients experienced more robust immune responses compared to a group with non-modified hTERT due to a stronger hTERT specific CD4+ and CD8+ T-cell responses.⁶⁹ The results of treatment showed 95% immune response rate, which was evidenced by a reduction of prostate-specific antigen (PSA) in circulating tumor cells.^{42,69} and consistent hTERT-specific T cell responses providing a good baseline for future clinical trials. A phase II clinical trial of GRNVAC1 administered to 21 of 33 enrolled AML patients, 19 of which were in clinical remission (CR), with 16/19 in CR1 (8 – intermediate risk and 8 – high risk of relapse), 3/19 in CR2, and 2 in early relapse, showed 55% immune response rate with one patient only developing adverse effects after short vaccination time. An estimate disease free survival at 12 months was 79% for 19CR patients, with 75% for intermediate and 81% for high risk of relapse patients.^{71,73} These results indicate that prolonged vaccination of patients with up to 32 administrations of GRNVAC1 can be well tolerated with no major toxicities in most patients, producing greater effect on high-risk of relapse AML patients⁷¹ (Table 4). Recently developed GRNVAC2 is designed using the same dendritic cell approach except that the DCs are being derived from human embryonic stem cells (hESCs) instead of leukapheresis of each individual patient, and is thus a better vaccine delivery system.⁷⁴

Telomerase based gene therapies

Oncolytic and suicide gene therapies

Telomelysin (OB-301) (Oncolys BioPharma Inc., Tokyo, Japan), Ad-hTERT/hTERT-NTR/CB1954 and hTERTp-HRP/IAA.

See Supplement for additional information.

Other telomerase inhibiting strategies

G-quadruplex stabilizers

G-quadruplex stabilizers are potent ligands that indirectly target telomerase resulting in inhibition of its catalytic activity. G-quadruplex ligands stabilize or promote G-quadruplex structure by preventing G-quadruplex from unwinding and opening the telomeric ends to telomerase thus locking the single stranded telomeric substrate within the T-loop. G-quadruplex ligands may also trigger telomere uncapping by causing dissociation of telomere-associated proteins.^{3,19} Most of the G-quadruplex stabilizing ligands contain a polycyclic heteroaromatic structure. BRACO-19, RHPS4 and Telomestatin are three of the most commonly studied G-quadruplex binding ligands. They inhibit telomerase by activat-

ing DNA damage responses similar to those activated in response to dsDNA breaks.²¹

Telomestatin – a natural macrocyclic compound

Telomestatin has been one of the most potent small molecule G-quadruplex stabilizers to date, with high selectivity for tumor cells and with minimal effects on normal cells. Telomestatin is a natural product with a complex structure composed of a large array of polyoxazole rings that form macrocyclic linkages (Telomestatin-R).^{75,76} Studies have shown that telomestatin may promote formation and stabilization of G-quadruplex structure by binding to G-quadruplex guanosines at both termini and sandwiching the G-quadruplex in a 2:1 complex.⁷⁷ Telomestatin may also cause earlier than expected telomere shortening in various tumors, indicating that factors other than telomerase inhibition may be contributing to this effect. Telomestatin induces activation of apoptosis in acute leukemia cells as evidenced by activation of p38 MAP kinase, caspase-3 and poly-(ADP-ribose) polymerase (PARP).⁷⁸ Telomestatin has also shown inhibition of telomerase activity and tumor cell proliferation at low IC₅₀ values in various tumor cell lines, including myeloma, neuroblastoma, myeloid leukemia, breast, pancreatic, cervical and some other cancer cell lines.^{78–82} In addition, telomestatin was found to either significantly down regulate important telomeric proteins, such as POT1 and TRF2, or result in complete dissociation of TRF2, as seen in HT1080 fibrosarcoma cell lines,⁸¹ thus leading to uncapping of telomeres with shortening of both single and double stranded telomeric sequence.^{80,81} A major limitation of telomestatin is the difficulty of its synthesis, making it unfeasible for large-scale production.⁸³ A recent study has reported the development of a new (S)-stereoisomer of telomestatin-(R), which has shown four-fold greater telomerase inhibiting activity than the (R)-stereoisomer.⁸⁴ However, future research is necessary to discover a better method for telomestatin synthesis to enable its application for patient use.

BRACO-19 (trisubstituted acridine G-quadruplex Ligand) and RHPS4 (polycyclic acridinium G-quadruplex ligand)

BRACO-19 and RHPS4 are promising small molecule G-quadruplex stabilizing ligands, similar in structure to telomestatin but with less tumor selectivity. Studies have shown that BRACO19 may be a successful single agent therapy for tumors with shorter telomeres and RHPS4 may be best when used in combination with other therapies.^{85–87} Further details may be found in the Supplemental section.

Targeting telomere and telomerase-associated proteins

Tankyrase inhibitors

Studies have shown that inhibition of tankyrases may lead to inhibition of residual telomerase activity, which is often seen in drug resistant tumors, and could potentially sensitize cells that became resistant to telomerase inhibitors.^{88–90} Tankyrase 1 and 2 (TNKS1 and TNKS2) belong to the family of telomerase-specific poly (ADP-ribose) polymerases (PARPs).^{91,92} TNKS1 is activated by binding to DNA breaks and takes part in DNA base excision repair.⁹⁰ TNKS1 can modify telomere structure by exposing telomeric DNA to telomerase.⁹³ The telomeric DNA binding protein TRF1 is a negative regulator of telomere length, which blocks telomerase access to telomeres.⁹² Removing TRF1 from telomeres allows telomerase access to telomeric DNA, leading to telomere elongation in telomerase positive cells.⁹⁴ TNKS1 causes poly (ADP-ribosylation) of TRF1 protein (PARsylation), reducing TRF1's binding to telomeric

DNA, leading to ubiquitination⁹⁵ and a complete release of TRF1 from the DNA strand.^{93,94} TNKS1 may directly contribute to telomere elongation by acting as a positive regulator of telomere length and causing the dissociation of TRF1 from telomeric DNA. Therefore targeting tankyrases with PARP inhibitors may be a new novel anticancer therapy approach.^{91,93}

See Supplement for additional information.

Inhibition of HSP90

Heat shock protein 90 (HSP90) is a molecular chaperone required for folding and regulation of its client proteins, many of which are required to promote cancer growth and survival. HSP90 is amplified in cancer cells and exists in multi-chaperone complexes highly dependent on ATP hydrolysis.⁹⁶ Inhibitors of HSP90 modulate signaling events in tumors by downregulating many tumorigenic proteins, causing their destabilization and degradation from the HSP90 complex.⁹⁶ Studies show that the HSP90-p23 co-chaperone complex is required for maturation and activation of telomerase.^{97,98} In a study with telomerase positive oral cancer cell lines it was found that HSP90-hTERT association was required for hTERT promoter activity in cancer cell lines and inhibition of HSP90 could lead to a proteasome-dependent degradation of hTERT.^{98,99}

Geldanamycin (GA) (INVIVOGEN, San Diego, California) is one example of HSP90 inhibitors, which acts through HSP90 and, in addition to other effects it has on HSP90, it blocks the ATP-dependent binding of HSP90 to p23, causing disruption of the chaperone assembly leading to inhibition of the telomerase.⁹⁷ Due to limited solubility and high hepatotoxicity, the analogues of GA, 17-AAG and 17-DAMG, have been developed and are currently in the phase I and phase II clinical trials.¹⁰⁰ A recent study showed that curcumin, which is a natural compound derived from turmeric,¹⁰¹ can cause time- and dose-dependent inhibition of nuclear localization of hTERT in the H1299 NSCLC cell line via proteasome-mediated degradation causing dissociation of p23 from hTERT complex. However, it does not have any effect on HSP90-hTERT binding, indicating that HSP90-p23 complex is required for telomerase activity.¹⁰² While it is still unclear how HSP90-p23 mediates nuclear translocation of hTERT from its nonfunctional state in the cytoplasm to a biologically functional state in the nucleus, inhibition of nuclear translocation of telomerase with curcumin or other HSP90-p23 inhibitors may be a promising approach in regulating telomerase translocation during tumorigenic development.¹⁰²

T-oligo

T-oligo is another novel anticancer agent, composed of a single stranded 11-base oligonucleotide sequence (GTTAGGGTTAG) that is homologous to the sequence of a single stranded telomeric overhang.^{103,104} Studies have shown that treating various tumor cell lines with T-oligo for a short time could activate potent DNA damage responses in tumor cell lines, mediated through the ATM kinase and its effector proteins such as p53, p57, p95/Nbs1, and E2F1.^{103–107} These responses were similar to DNA damage responses activated by uncapping of telomeres and those caused by a knockdown of TRF2, leading to activation of DNA damage signals and apoptosis in cancer cells.^{92,103,104} However, treating normal cells with T-oligo leads to only a transient cell cycle arrest, since normal cells unlike cancer cells have regular cell cycle check points^{5,103}. Other studies have shown that treatment with T-oligo can cause inhibition of angiogenesis in melanoma cell lines, resulting from a decrease in VEGF receptor signal¹⁰⁸ and a reduction of oxidative damage to cells.¹⁰⁹ Current studies on T-oligo show very promising results and future research is required to assess T-oligos' full potential.

Discussion and conclusion

Among various telomerase inhibitors reviewed, the AS-ODN inhibitor GRN163L, hTERT and DC based vaccines GV1001 and GRNVAC1 respectively, may be potential new treatment strategies. Treatment of various tumor cells lines with GRN163L *in vitro* and *in vivo* has shown not only inhibition of TA or tumor cell proliferation, but also inhibition of tumor metastasis, indicating its potential for treatment of metastatic cancers. One important finding is that GRN163L has shown inhibition of cancer stem cells or tumor initiating cells *in vitro* studies with various tumor cell lines, which may be of particular importance for treatment of highly proliferative tumor cell lines (See Supplement and Table 2 for more details). Phase I and II clinical trials were successful in determining MTDs and DLTs for GRN163L in patients with CLD, solid tumor malignancies, MM and breast cancer, with no major cytotoxicities seen, indicating GRN163L can be moved for testing into phase III clinical trials.

While BIBR1532 may not be as promising as GRN163L, studies have shown that it is a highly selective telomere length-dependent inhibitor, which may not be an ideal single therapy agent for most cancers but may be a good choice of treatment for cancers with short telomeres.³⁵ In addition BIBR1532 may be used as a combination therapy with standard of care or traditional therapy to sensitize certain drug-resistant cell lines to other chemotherapies.^{35,40}

GV1001 and GRNVAC1 are both promising telomerase targeting vaccines, capable of stimulating CD4+ and CD8+ responses in telomerase positive tumors, showing minimal effects on normal cells, low cytotoxicity and no autoimmunity. Clinical trials with GV1001 in patients with pancreatic adenocarcinoma, stage IV metastatic melanoma, and advanced stages of NSCLC and HCC, have shown good overall immune response rates, after short treatment times, ranging from 39% to 95% depending on tumor type, stage and dosage (Table 4). Larger and long-term studies may be required to further determine long-term toxicity of GV1001. Because patients with advanced stages of cancers have poor survival or may develop disease metastases, it is suggested that studying GV1001 in patients with less advanced stages may increase overall survival rates.^{46,110}

Compared to GV1001, GRNVAC1 vaccine has shown better efficacy in clinical trials, with stronger hTERT specific CD4+ T-cell responses, leading to IL-2 secretion and stimulating CTL-mediated tumor cell lysis. It has had good immune responses in patients with metastatic prostate tumors and AML, showing greater DFS in high-risk AML patients. If difficulties with DC vaccine production, such as DCs derivation and maturation could be easily overcome in the future trials, DC vaccines may become successful methods of immunogenic telomerase targeting.

Although small molecule inhibitors or immunotherapies may be effective methods of telomerase inhibition, there is always a concern that cells may gain resistance to direct telomerase inhibitors after excessive telomere shortening.⁸⁸ Thus, studying G-quadruplex stabilizers, tankyrase enzyme inhibitors and T-oligo may help to solve this problem.

While most of the telomerase targeting therapeutics showed success in preclinical or clinical studies, a combination therapy of telomerase inhibitors and standard of care or traditional therapy may be the most effective way to target telomerase positive tumors. This may help to overcome common issues with standard treatments, such as tumor relapse or recurrence and a long lag time, common for many telomerase targeting monotherapies. Combination therapy may increase drug efficacy causing critical telomerase shortening, antitumor mass shrinkage, and may require lower drug doses thus reducing cytotoxicity on normal cells.

Conflict of interest statement

No conflict of interest.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.ctrv.2012.06.007>.

References

- Blackburn EH. Telomerase and Cancer: Kirk A. Landon–AACR prize for basic cancer research lecture. *Mol Cancer Res* 2005;**3**:477–82.
- Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. *Nat Med* 2006;**12**:1133–8.
- Harley CB. Telomerase and cancer therapeutics. *Nat Rev Cancer* 2008;**8**:167–79.
- Tian X, Chen B, Liu X. Telomere and telomerase as targets for cancer therapy. *Appl Biochem Biotechnol* 2010;**160**:1460–72.
- Rankin AM, Faller DV, Spanjaard RA. Telomerase inhibitors and ‘T-oligo’ as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. *Anticancer Drugs* 2008;**19**:329–38.
- Bisoffi M, Heaphy CM, Griffith JK. Telomeres: prognostic markers for solid tumors. *Int J Cancer* 2006;**119**:2255–60.
- Dikmen ZG, Wright WE, Shay JW, Gryaznov SM. Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells. *J Cell Biochem* 2008;**104**:444–52.
- Artandi SE, DePinho RA. Telomeres and telomerase in cancer. *Carcinogenesis* 2010;**31**:9–18.
- Meyerson M. Role of telomerase in normal and cancer cells. *J Clin Oncol* 2000;**18**:2626–34.
- Corey DR. Telomerase: an unusual target for cytotoxic agents. *Chem Res Toxicol* 2000;**13**:957–60.
- Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. *Br J Cancer* 2008;**98**:677–83.
- Shay JW. Telomerase as a target for cancer therapeutics. In: Roth JA, editor. *Gene-based therapies for cancer, current cancer research*. New York, London: Springer; 2010. p. 231–49.
- Gellert GC, Jackson SR, Dikmen ZG, Wright WE, Shay JW. Telomerase as a therapeutic target in cancer. *Drug Discov Today Dis Mech* 2005;**2**:159–64.
- Kelland LR. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics—current status and future prospects. *Eur J Cancer* 2005;**41**:971–9.
- Ulaner GA. Telomere maintenance in clinical medicine. *Am J Med* 2004;**117**:262–9.
- Phatak P, Burger AM. Telomerase and its potential for therapeutic intervention. *Br J Pharmacol* 2007;**152**:1003–11.
- Riethman H. Human telomere structure and biology. *Annu Rev Genomics Hum Genet* 2008;**9**:1–19.
- Ou TM, Lu YJ, Tan JH, Huang ZS, Wong KY, Gu LQ. G-quadruplexes: targets in anticancer drug design. *ChemMedChem* 2008;**3**:690–713.
- Xu Y. Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA. *Chem Soc Rev* 2011;**40**:2719–40.
- Zaug AJ, Podell ER, Cech TR. Human POT1 disrupts telomeric G-quadruplexes allowing telomerase extension in vitro. *Proc Natl Acad Sci U S A* 2005;**102**:10864–9.
- Neidle S. Human telomeric G-quadruplex: the current status of telomeric G-quadruplexes as therapeutic targets in human cancer. *FEBS J* 2010;**277**:1118–25.
- Burger AM. Highlights in experimental therapeutics. *Cancer Lett* 2007;**245**:11–21.
- Cunningham AP, Love WK, Zhang RW, Andrews LG, Tollefsbol TO. Telomerase inhibition in cancer therapeutics: molecular-based approaches. *Curr Med Chem* 2006;**13**:2875–88.
- Roth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L) – telomerase-based cancer therapy. *Recent Results Cancer Res* 2010;**184**:221–34.
- Baker N. Targeting telomerase and telomeres by novel anticancer compounds. *MMG 445 Basic Biotechnol* 2008;**4**.
- Tressler RJ, Chin AC, Feldman EJ, Rai KR, Kornbrust D, Harley CB, et al. GRN163L, a potent and specific inhibitor of telomerase: integrated pharmacokinetic, pharmacodynamic, and safety data guides design of practical treatment regimens for targeting inhibitory levels in patients. *ASH Ann Meeting Abstr* 2006;**108**:2595.
- Kozloff M, Sledge GW, Benedetti FM, Starr A, Wallace JA, Stuart MJ, et al. Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). *J Clin Oncol (Meeting Abstr)* 2010;**28**:2598.
- Chanan-Khan AA, Munshi NC, Hussein MA, Elias L, Benedetti F, Smith J, et al. Results of a phase I study of GRN163L, a direct inhibitor of telomerase, in patients with relapsed and refractory multiple myeloma (MM). *ASH Ann Meeting Abstr* 2008;**112**:3688.
- Ratain MJ, Heath E, Weise A, Elias L, Benedetti FM, Smith JA, et al. Abstract C169: intermittent dosing of Imetelstat Sodium, a telomerase inhibitor, induces drug exposure consistent with in vivo tumor growth inhibition. *Mol Cancer Ther* 2009;**8**:C169.
- Geron Corporation. In: ClinicalTrials.gov [Internet]. Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocytopenia or Polycythemia Vera (ET/PV). 2010. <<http://www.clinicaltrials.gov/ct2/show/NCT01243073>>. [cited 2011 Feb 12].
- Goldblatt EM, Erickson PA, Gentry ER, Gryaznov SM, Herbert BS. Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab. *Breast Cancer Res Treat* 2009;**118**:21–32.
- Pascolo E, Wenz C, Lingner J, Huel N, Priepke H, Kauffmann I, et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. *J Biol Chem* 2002;**277**:15566–72.
- El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. *Blood* 2005;**105**:1742–9.
- Chen H, Li Y, Tollefsbol TO. Strategies targeting telomerase inhibition. *Mol Biotechnol* 2009;**41**:194–9.
- Parsch D, Brassat U, Brummendorf TH, Fellenberg J. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines. *Cancer Invest* 2008;**26**:590–6.
- Damm K, Hemmann U, Garin-Chesa P, Huel N, Kauffmann I, Priepke H, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. *EMBO J* 2001;**20**:6958–68.
- Mueller S, Hartmann U, Mayer F, et al. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors. *Invest New Drugs* 2007;**519**:24.
- Brassat U, Balabanov S, Bali D, Dierlamm J, Braig M, Hartmann U, et al. Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells. *Exp Hematol* 2011;**39**:66 [76.e2].
- Roth A, Durig J, Himmelreich H, Bug S, Siebert R, Duhrsen U, et al. Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. *Leukemia* 2007;**21**:2456–62.
- Ward RJ, Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. *Mol Pharmacol* 2005;**68**:779–86.
- Keith WN, Bilsland AE. Targeting telomerase: therapeutic options for cancer treatment. In: Rudolph KL, editor. *Telomeres and telomerase in ageing, disease, and cancer*. Berlin Heidelberg: Springer-Verlag; 2008. p. 247–83.
- Beatty GL, Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines. *Expert Rev Vaccines* 2008;**7**:881–7.
- Vonderheide RH. Prospects and challenges of building a cancer vaccine targeting telomerase. *Biochimie* 2008;**90**:173–80.
- Kyte JA. Cancer vaccination with telomerase peptide GV1001. *Expert Opin Investig Drugs* 2009;**18**:687–94.
- Middleton G, Ghaneh P, Costello E, Greenhalf W, Neoptolemos JP. New treatment options for advanced pancreatic cancer. *Expert Rev Gastroenterol Hepatol* 2008;**2**:673–96.
- Nava-Parada P, Emens LA. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. *Curr Opin Mol Ther* 2007;**9**:490–7.
- Shaw VE, Naisbitt DJ, Costello E, Greenhalf W, Park BK, Neoptolemos JP, et al. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. *Expert Rev Vaccines* 2010;**9**:1007–16.
- Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. *J Immunol* 2008;**180**:3122–31.
- Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. *Cancer Immunol Immunother* 2008;**57**:1719–26.
- Kokhaei P, Palma M, Hansson L, Osterborg A, Mellstedt H, Choudhury A. Telomerase (hTERT 611–626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. *Exp Hematol* 2007;**35**:297–304.
- Kyte JA, Trachsel S, Risberg B, Thor Straten P, Lislerud K, Geudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. *Cancer Immunol Immunother* 2009;**58**:1609–26.
- Lytix Biopharma AS. In: ClinicalTrials.gov [Internet]. Norway. A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma. 2010. <<http://www.clinicaltrials.gov/ct2/show/NCT01223209>>. [cited 2011 Feb 12].
- Buanes T, Bernhardt S, Rosendahl L, Moeller M, Trachel S, Ikdahl T, et al. Immunotherapy of patients with pancreatic adenocarcinoma: Influence of adjuvants. *ASCO Meeting Abstr J Clin Oncol* 2008;**26**:15542.
- Bernhardt SL, Gjertsen MK, Trachsel S, Moller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. *Br J Cancer. J Clin Oncol* 2006;**95**:1474–82.
- Bernhardt SL, Buanes TA, Moller M, Eriksen J. A., Geudernack G. Imiquimod a new adjuvant for telomerase peptide vaccine: A phase I trial in patients with inoperable pancreatic cancer. *ASCO Meeting Abstr J Clin Oncol* 2005;**23**:9623.
- Choudhury A, Mosolits S, Staff C, Liljefors M, Mozaffari F, Moller M, et al. Treatment of advanced pancreatic cancer patients with a telomerase-peptide vaccine together with gemcitabine: a phase II clinical study. *AACR Meeting Abstr* 2007;**2007**:1863.

57. Greten TF, Forner A, Korangy F, N'Kontchou G, Barget N, Ayuso C, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. *BMC Cancer* 2010;**10**:209.
58. Buanes T, Maurel J, Liauw W, Hebbar M, Nemunaitis J. A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC). *J Clin Oncol (Meeting Abstr)* 2009;**27**.
59. Royal Liverpool University Hospital. In: ClinicalTrials.gov [Internet]. UK. Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer. 2009. <<http://www.clinicaltrials.gov/ct2/show/NCT00425360>> [cited 2011 Feb 12].
60. Aamdal S, Dueland S, Engebraaten O, Owre K, Dyrhaug M, Trachsel S, et al. A phase I/II study of telomerase peptide vaccination in combination with chemotherapy in patients with stage IV malignant melanoma. *J Clin Oncol (Meeting Abstr)* 2006;**24**.
61. Menez-Jamet J, Kosmatopoulos K. Development of optimized cryptic peptides for immunotherapy. *IDrugs* 2009;**12**:98–102.
62. Mavroudis D, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, et al. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. *Oncology* 2006;**70**:306–14.
63. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. *Eur J Immunol* 2000;**30**:3411–21.
64. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. *J Clin Oncol* 2007;**25**:2727–34.
65. Vetsika EK, Konsolakis G, Bolonaki E, Kotsakis A, Papadimitraki E, Christou N, et al. Immune responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. *AACR Meeting Abstr* 2008;**2008**:2541.
66. Kotsakis A, Vetsika K, Christou N, Drogaris M, Pantazopoulos N, Aggouraki D, et al. Clinical and immunologic response of patients with advanced solid tumors vaccinated with an optimized cryptic hTERT peptide (Vx-001). *ASCO Meeting Abstr* 2008;**26**:3030.
67. Kosmatopoulos K, Bolonaki E, Aggouraki D, Nikoloudi E, Kanellou P, Papadimitraki E, et al. Clinical efficacy and immunogenicity of the optimized cryptic peptide TERT572Y vaccine (Vx-001) in patients with advanced non-small cell lung cancer (NSCLC). *ASCO Meeting Abstr* 2006;**24**:17069.
68. Huo LF, Tang JW, Huang JJ, Huang PT, Huang CF, Kung HF, et al. Cancer immunotherapy targeting the telomerase reverse transcriptase. *Cell Mol Immunol* 2006;**3**:1–11.
69. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. *J Immunol* 2005;**174**:3798–807.
70. Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V, et al. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. *Cancer Res* 2002;**62**:5041–8.
71. DiPersio JF, Collins Jr RH, Blum W, Devetten MP, Stiff P, Elias L, et al. Immune responses in AML patients following vaccination with GRNVAC1, autologous RNA transfected dendritic cells expressing telomerase catalytic subunit hTERT. *ASH Annu Meeting Abstr* 2009;**114**:633.
72. Srivastava R, Wolfrain L, Spink A, Talib S, Davies A, Shivakumar R, et al. Development of a rapid, closed, large-scale cell loading process for the manufacture of telomerase mRNA-transfected dendritic cell cancer vaccine GRNVAC1. *J Immunother* 2006;**29**:656.
73. Khoury HJ, Collins Jr RH, Blum W, Maness L, Stiff P, Kelsey SM, et al. Prolonged administration of the telomerase vaccine GRNVAC1 is well tolerated and appears to be associated with favorable outcomes in high-risk acute myeloid leukemia (AML). *ASH Ann Meeting Abstr* 2010;**116**:2190.
74. Brower V. Telomerase-based therapies emerging slowly. *J Natl Cancer Inst* 2010;**102**:520–1.
75. Shin-ya K, Wierzba K, Matsuo K, Ohtani T, Yamada Y, Furihata K, et al. Telomestatin, a novel telomerase inhibitor from *Streptomyces anulatus*. *J Am Chem Soc* 2001;**123**:1262–3.
76. Doi T, Yoshida M, Shin-ya K, Takahashi T. Total synthesis of (R)-telomestatin. *Org Lett* 2006;**8**:4165–7.
77. Kim MY, Vankayalapati H, Shin-ya K, Wierzba K, Hurley LH. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. *J Am Chem Soc* 2002;**124**:2098–9.
78. Tauchi T, Shin-ya K, Sashida G, Sumi M, Okabe S, Ohyashiki JH, et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. *Oncogene* 2006;**25**:5719–25.
79. Sumi M, Tauchi T, Sashida G, Nakajima A, Gotoh A, Shin-ya K, et al. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. *Int J Oncol* 2004;**24**:1481–7.
80. Tahara H, Shin-ya K, Seimiya H, Yamada H, Tsuruo T, Ide T. G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells. *Oncogene* 2006;**25**:1955–66.
81. Gomez D, Wenner T, Brassart B, Douarre C, O'Donohue MF, El Khoury V, et al. Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells. *J Biol Chem* 2006;**281**:38721–9.
82. Binz N, Shalaby T, Rivera P, Shin-ya K, Grotzer MA. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. *Eur J Cancer* 2005;**41**:2873–81.
83. Monchaud D, Granzhan A, Saettel N, Guedin A, Mergny JL, Teulade-Fichou MP. "One ring to bind them all"—part I: the efficiency of the macrocyclic scaffold for G-quadruplex DNA recognition. *J Nucleic Acids* 2010;**2010**:525862.
84. Doi T, Shibata K, Yoshida M, Takagi M, Tera M, Nagasawa K, et al. (S)-stereoisomer of telomestatin as a potent G-quadruplex binder and telomerase inhibitor. *Org Biomol Chem* 2011;**9**:387–93.
85. Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. *Mol Pharmacol* 2002;**61**:1154–62.
86. Haider SM, Neidle S. A molecular model for drug binding to tandem repeats of telomeric G-quadruplexes. *Biochem Soc Trans* 2009;**37**:583–8.
87. Taetz S, Baldes C, Murdter TE, Kleideiter E, Piotrowska K, Bock U, et al. Biopharmaceutical characterization of the telomerase inhibitor BRACO19. *Pharm Res* 2006;**23**:1031–7.
88. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. *Cancer Cell* 2005;**7**:25–37.
89. Hiyama K. *Telomeres and telomerase in cancer*. Springer; 2009.
90. Munoz-Gamez JA, Quiles-Perez R, Ruiz-Extremera A, Martin-Alvarez AB, Sanjuan-Nunez L, Carazo A, et al. Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells. *Cancer Lett* 2011;**301**:47–56.
91. Cook BD, Dynek JN, Chang W, Shostak G, Smith S. Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. *Mol Cell Biol* 2002;**22**:332–42.
92. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. *Cell* 1998;**92**:401–13.
93. Smith S, Giriati I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. *Science* 1998;**282**:1484–7.
94. Hsiao SJ, Smith S. Tankyrase function at telomeres, spindle poles, and beyond. *Biochimie* 2008;**90**:83–92.
95. Chang W, Dynek JN, Smith S. TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres. *Genes Dev* 2003;**17**:1328–33.
96. Koga F, Kihara K, Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. *Anticancer Res* 2009;**29**:797–807.
97. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, Ouellette M, et al. Functional requirement of p23 and Hsp90 in telomerase complexes. *Genes Dev* 1999;**13**:817–26.
98. Kim RH, Kim R, Chen W, Hu S, Shin KH, Park NH, et al. Association of hsp90 to the hTERT promoter is necessary for hTERT expression in human oral cancer cells. *Carcinogenesis* 2008;**29**:2425–31.
99. Mizuno H, Khurts S, Seki T, Hirota Y, Kaneko S, Murakami S. Human telomerase exists in two distinct active complexes in vivo. *J Biochem* 2007;**141**:641–52.
100. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. *Endocr Relat Cancer* 2006;**13**(Suppl 1):S125–35.
101. Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, Rao CV, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. *Cancer Res* 1999;**59**:597–601.
102. Lee JH, Chung IK. Curcumin inhibits nuclear localization of telomerase by dissociating the Hsp90 co-chaperone p23 from hTERT. *Cancer Lett* 2010;**290**:76–86.
103. Yaar M, Eller MS, Panova I, Kubera J, Wee LH, Cowan KH, et al. Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. *Breast Cancer Res* 2007;**9**:R13.
104. Eller MS, Puri N, Hadshiew IM, Venna SS, Gilchrist BA. Induction of apoptosis by telomere 3' overhang-specific DNA. *Exp Cell Res* 2002;**276**:185–93.
105. Puri N, Eller MS, Byers HR, Dykstra S, Kubera J, Gilchrist BA. Telomere-based DNA damage responses: a new approach to melanoma. *FASEB J* 2004;**18**:1373–81.
106. Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, Gilchrist BA, et al. Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. *Int J Cancer* 2009;**124**:473–82.
107. Gnanasekar M, Thirugnanam S, Zheng G, Chen A, Ramaswamy K. T-oligo induces apoptosis in advanced prostate cancer cells. *Oligonucleotides* 2009;**19**:287–92.
108. Coleman C, Levine D, Kishore R, Qin G, Thorne T, Lambers E, et al. Inhibition of melanoma angiogenesis by telomere homolog oligonucleotides. *J Oncol* 2010;**2010**:928628.
109. Lee MS, Yaar M, Eller MS, Runger TM, Gao Y, Gilchrist BA. Telomeric DNA induces p53-dependent reactive oxygen species and protects against oxidative damage. *J Dermatol Sci* 2009;**56**:154–62.
110. Brunsvig P, Aamdal S, Gjertsen M, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. *Cancer Immunol Immunother* 2006;**1553**–64.

111. Batista LF, Artandi SE. Telomere uncapping, chromosomes, and carcinomas. *Cancer Cell* 2009;**15**:455–7.
112. Brennan SK, Wang Q, Tressler R, Harley C, Go N, Bassett E, et al. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. *PLoS One* 2010;**5**: e12487.
113. Shamma MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. *Leukemia* 2008;**22**:1410–8.
114. Jackson SR, Zhu CH, Paulson V, Watkins L, Dikmen ZG, Gryaznov SM, et al. Antiadhesive effects of GRN163L—an oligonucleotide N3'→P5' thio-phosphoramidate targeting telomerase. *Cancer Res* 2007;**67**:1121–9.
115. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. *Cancer Res* 2005;**65**:7866–73.
116. Uziel O, Beery E, Dronichev V, Samocha K, Gryaznov S, Weiss L, et al. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms. *PLoS One* 2010;**5**:e9132.
117. Gomez-Millan J, Goldblatt EM, Gryaznov SM, Mendonca MS, Herbert BS. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. *Int J Radiat Oncol Biol Phys* 2007;**67**: 897–905.
118. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. *Breast Cancer Res Treat* 2006;**96**:73–81.
119. Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. *Clin Cancer Res* 2006;**12**: 3184–92.
120. Goldblatt EM, Gentry ER, Fox MJ, Gryaznov SM, Shen C, Herbert BS. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. *Mol Cancer Ther* 2009;**8**:2027–35.
121. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey 2nd WH. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. *Neuro Oncol* 2008;**10**:112–20.
122. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. *Clin Cancer Res* 2010;**16**:154–63.
123. Marian CO, Wright WE, Shay JW. The effects of telomerase inhibition on prostate tumor-initiating cells. *Int J Cancer* 2010;**127**:321–31.
124. Djojusbrotto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. *Hepatology* 2005;**42**:1127–36.
125. Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, Pattamatta P, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. *Cancer Res* 2010;**70**:9494–504.
126. Shamma MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, et al. Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. *Clin Cancer Res* 2008;**14**:4971–80.
127. Brunsvig PF, Gjertsen MK, Kvalheim G, Aamdal S, Markowski-Grimsru CJ, Sve I, et al. A phase I/II study of telomerase peptide vaccination of patients with non-small cell lung cancer. ASCO Meeting Abstracts. *J Clin Oncol* 2005;**23**: 2580.
128. Kosmatopoulos K, Bolonaki E, Kotsakis A, Papadimitraki E, Agouraki D, Kosnoslakis G, et al. Vaccination of patients with advanced non-small cell lung cancer with an optimized cryptic hTERT peptide (Vx-001). *ASCO Meeting Abstr* 2007;**25**:7642.
129. Ratain MJ, Benedetti FM, Janisch L, Khor S, Schilsky RL, Cohen EE, et al. A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors. *J Clin Oncol (Meeting Abstr)* 2008;**26**:3581.